This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chou, T C Articles by Fox, J J Search for Related Content PubMed PubMed Citation Articles by Chou, T C Articles by Fox, J J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 September; 31(9): 1355-1358

Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil.

T C Chou, X B Kong, M P Fanucchi, Y C Cheng, K Takahashi, K A Watanabe and J J Fox

Laboratory of Pharmacology, Sloan-Kettering Institute for Cancer Research, New York, New York 10021.

ABSTRACT

2'-Fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil (FEAU) was synthesized, and its biological activities were compared with those of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU). Earlier studies indicated that both compounds showed potent anti-herpes simplex virus activity, with a 50% effective dose (ED50) of less than 0.25 microM. In the present study the cell growth inhibitory activity of FEAU (ED50, 200 to 2,060 microM) was found to be about 100-fold less than that of FMAU. With an ED50 ranging from 630 to 3,700 microM, FEAU only weakly inhibited thymidine incorporation into DNA, as compared with FMAU with an ED50 of 9 to 28 microM. Following exposure to [2-14C]FEAU (100 microM), 0.48 pmol/10(6) cells per h was incorporated into the DNA of herpes simplex virus type 1-infected Vero cells, whereas no detectable incorporation was found in uninfected Vero cells or L1210 cells. The Ki of FEAU for thymidine kinase purified from human leukemic cells was greater than 150 microM. For herpes simplex virus type 1- and 2-encoded thymidine kinases, the Kis were 0.6 and 0.74 microM, respectively. Both FEAU and FMAU were relatively nontoxic for mice, with a 50% lethal dose of greater than 800 mg/kg per day (four intraperitoneal doses). However, the lethal dose of FEAU for dogs was 100 mg/kg per day (10 intravenous doses), a dose which is 40- to 80-fold greater than the toxic dose of FMAU. These results suggest that FEAU is a worthy candidate for further development as an antiherpetic agent.

---

Antimicrob Agents Chemother. 1987 September; 31(9): 1355-1358

This article has been cited by other articles:

• Krug, P. W., Schinazi, R. F., Hilliard, J. K. (2010). Inhibition of B Virus (Macacine herpesvirus 1) by Conventional and Experimental Antiviral Compounds. Antimicrob. Agents Chemother. 54: 452-459 [Abstract] [Full Text]  
• Bading, J. R., Shields, A. F. (2008). Imaging of Cell Proliferation: Status and Prospects. JNM 49: 64S-80S [Abstract] [Full Text]  
• Miyagawa, T., Gogiberidze, G., Serganova, I., Cai, S., Balatoni, J. A., Thaler, H. T., Ageyeva, L., Pillarsetty, N., Finn, R. D., Blasberg, R. G. (2008). Imaging of HSV-tk Reporter Gene Expression: Comparison Between [18F]FEAU, [18F]FFEAU, and Other Imaging Probes. JNM 49: 637-648 [Abstract] [Full Text]  
• Chou, T.-C. (2006). Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 58: 621-681 [Abstract] [Full Text]